文献速递糖尿病

在儿童及成人自身免疫性糖尿病中鉴定IA-2(ICA512)氨基端独特抗原决定簇:新型生物标志物开发

Identification of Unique Antigenic Determinants in the Amino Terminus of IA-2 (ICA512) in Childhood and Adult Autoimmune Diabetes: New Biomarker Development.
PubMed 文献 · Diabetes Care · 2017-02-07

研究在258例临床诊断2型糖尿病(病程0.01-31年)和150例新诊断1型糖尿病(病程0.04-0.49年)患者中评估检测IA-2胞外域(IA-2ec)自身抗体的新型生物标志物,并在1型糖尿病和2型糖尿病患者中检测IA-2胞内域、GAD65及锌转运体8抗体。IA-2ec抗体在1型糖尿病患者中检出,且在5%无其他IA-2表位或其他胰岛自身抗原血清学反应的2型糖尿病患者中检出。用IA-2ec衍生肽刺激1型糖尿病(n=18)及HLA匹配健康者(n=13)外周血单个核细胞并行肽/DQ8特异性四聚体染色,观察到针对IA-2ec内既往未报告表位的疾病相关反应。

要点

  • IA-2ec抗体在1型糖尿病患者中检出,并在5%无其他胰岛自身抗体反应的临床诊断2型糖尿病患者中检出。
  • IA-2ec衍生肽可在1型糖尿病及HLA匹配健康者中 elicit 针对既往未报告表位的疾病相关CD4+ T细胞反应。
  • 作者认为胰岛自身免疫在临床诊断2型糖尿病中可能比既往观察更常见。

核心结论

  • 开发出可识别IA-2 N端新抗原决定簇的新型抗体生物标志物。
  • IA-2ec自身抗体可在1型糖尿病患者及常规胰岛自身抗体检测阴性的成人2型糖尿病表型自身免疫患者亚组中检出。
  • 这些观察提示胰岛自身免疫在临床诊断2型糖尿病中可能比既往观察更常见。

研究设计与样本

  • 评估临床诊断2型糖尿病患者258例(病程0.01-31年),采用检测IA-2胞外域(IA-2ec)自身抗体的新型生物标志物。
  • 评估新诊断1型糖尿病患者150例(病程0.04-0.49年)中IA-2ec自身抗体的比例。
  • 检测IA-2胞内域、GAD65及锌转运体8自身抗体。
  • 用IA-2ec衍生肽刺激1型糖尿病患者18例及HLA匹配健康者13例外周血单个核细胞,并行肽/DQ8特异性四聚体染色。

主要发现

  • IA-2ec自身抗体在1型糖尿病患者中检出,并在5%无其他IA-2抗原表位或其他胰岛自身抗原血清学反应的2型糖尿病患者中检出。
  • 在1型糖尿病(n=18)及HLA匹配健康者(n=13)中观察到针对IA-2ec内既往未报告表位的疾病相关T细胞反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The characterization of diverse subtypes of diabetes is a dynamic field of clinical research and an active area of discussion. The objective of this study was to identify new antigenic determinants in the neuroendocrine autoantigen IA-2 (ICA512) and assess whether circulating autoantibodies directed to new IA-2 epitopes identify autoimmune diabetes in young and adult populations with diabetes. RESEARCH DESIGN AND METHODS: Clinically diagnosed patients with type 2 diabetes (n = 258; diabetes duration: 0.01-31 years) were evaluated using a new biomarker detecting autoantibodies directed to the extracellular domain of the neuroendocrine autoantigen IA-2 (IA-2ec). The proportion of IA-2ec autoantibodies was also evaluated in newly diagnosed patients with type 1 diabetes (n = 150; diabetes duration: 0.04-0.49 years). In addition, IA-2 (intracellular domain), GAD65, and zinc transporter 8 autoantibodies were assayed. RESULTS: IA-2ec autoantibodies were detected in patients with type 1 diabetes and, surprisingly, in 5% of patients with type 2 diabetes without serologic responses to other IA-2 antigenic epitopes or other islet autoantigens. We also assessed the ability of IA-2ec-derived peptides to elicit CD4+ T-cell responses by stimulating peripheral blood mononuclear cells from patients with type 1 diabetes (n = 18) and HLA-matched healthy subjects (n = 13) with peptides and staining with the peptide/DQ8-specific tetramers, observing disease-associated responses to previously unreported epitopes within IA-2ec. CONCLUSIONS: We developed a new antibody biomarker identifying novel antigenic determinants within the N terminus of IA-2. IA-2ec autoantibodies can be detected in patients with type 1 diabetes and in a subgroup of adult autoimmune patients with type 2 diabetes phenotype negative for conventional islet autoantibody testing. These observations suggest that islet autoimmunity may be more common in clinically diagnosed type 2 diabetes than previously observed.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Acevedo-Calado M, James EA, Morran MP, et al. Identification of Unique Antigenic Determinants in the Amino Terminus of IA-2 (ICA512) in Childhood and Adult Autoimmune Diabetes: New Biomarker Development. Diabetes Care. 2017. PMID: 28174261. doi:10.2337/dc16-1527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。